Zoetis Inc. (0M3Q.L)
USD 169.5
(-0.56%)
USD 169.5
(-0.56%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 8.54 Billion USD | 5.74% |
| 2022 | 8.08 Billion USD | 3.91% |
| 2021 | 7.77 Billion USD | 16.49% |
| 2020 | 6.67 Billion USD | 6.63% |
| 2019 | 6.26 Billion USD | 7.47% |
| 2018 | 5.82 Billion USD | 9.76% |
| 2017 | 5.3 Billion USD | 8.57% |
| 2016 | 4.88 Billion USD | 2.58% |
| 2015 | 4.76 Billion USD | -0.42% |
| 2014 | 4.78 Billion USD | 4.91% |
| 2013 | 4.56 Billion USD | 5.19% |
| 2012 | 4.33 Billion USD | 2.43% |
| 2011 | 4.23 Billion USD | 18.17% |
| 2010 | 3.58 Billion USD | 29.78% |
| 2009 | 2.76 Billion USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 2.36 Billion USD | 7.81% |
| 2024 Q1 | 2.19 Billion USD | -1.04% |
| 2024 Q3 | 2.38 Billion USD | 1.14% |
| 2023 Q2 | 2.18 Billion USD | 9.0% |
| 2023 FY | 8.54 Billion USD | 5.74% |
| 2023 Q1 | 2 Billion USD | -1.96% |
| 2023 Q3 | 2.15 Billion USD | -1.33% |
| 2023 Q4 | 2.21 Billion USD | 2.88% |
| 2022 Q1 | 1.98 Billion USD | 0.97% |
| 2022 FY | 8.08 Billion USD | 3.91% |
| 2022 Q4 | 2.04 Billion USD | 1.9% |
| 2022 Q3 | 2 Billion USD | -2.44% |
| 2022 Q2 | 2.05 Billion USD | 3.32% |
| 2021 Q4 | 1.96 Billion USD | -1.16% |
| 2021 Q2 | 1.94 Billion USD | 4.12% |
| 2021 FY | 7.77 Billion USD | 16.49% |
| 2021 Q3 | 1.99 Billion USD | 2.16% |
| 2021 Q1 | 1.87 Billion USD | 3.54% |
| 2020 Q4 | 1.8 Billion USD | 1.18% |
| 2020 FY | 6.67 Billion USD | 6.63% |
| 2020 Q1 | 1.53 Billion USD | -8.36% |
| 2020 Q2 | 1.54 Billion USD | 0.91% |
| 2020 Q3 | 1.78 Billion USD | 15.37% |
| 2019 Q1 | 1.45 Billion USD | -6.97% |
| 2019 Q4 | 1.67 Billion USD | 5.68% |
| 2019 FY | 6.26 Billion USD | 7.47% |
| 2019 Q3 | 1.58 Billion USD | 2.39% |
| 2019 Q2 | 1.54 Billion USD | 6.32% |
| 2018 Q2 | 1.41 Billion USD | 3.59% |
| 2018 Q1 | 1.36 Billion USD | -6.44% |
| 2018 FY | 5.82 Billion USD | 9.76% |
| 2018 Q4 | 1.56 Billion USD | 5.68% |
| 2018 Q3 | 1.48 Billion USD | 4.59% |
| 2017 Q3 | 1.34 Billion USD | 6.15% |
| 2017 Q1 | 1.23 Billion USD | -3.6% |
| 2017 FY | 5.3 Billion USD | 8.57% |
| 2017 Q4 | 1.46 Billion USD | 8.39% |
| 2017 Q2 | 1.26 Billion USD | 3.09% |
| 2016 Q3 | 1.24 Billion USD | 2.73% |
| 2016 FY | 4.88 Billion USD | 2.58% |
| 2016 Q1 | 1.16 Billion USD | -8.79% |
| 2016 Q2 | 1.2 Billion USD | 3.96% |
| 2016 Q4 | 1.27 Billion USD | 2.9% |
| 2015 FY | 4.76 Billion USD | -0.42% |
| 2015 Q4 | 1.27 Billion USD | 4.94% |
| 2015 Q3 | 1.21 Billion USD | 3.32% |
| 2015 Q2 | 1.17 Billion USD | 6.62% |
| 2015 Q1 | 1.1 Billion USD | -16.52% |
| 2014 FY | 4.78 Billion USD | 4.91% |
| 2014 Q4 | 1.32 Billion USD | 9.09% |
| 2014 Q3 | 1.21 Billion USD | 4.49% |
| 2014 Q1 | 1.09 Billion USD | -12.52% |
| 2014 Q2 | 1.15 Billion USD | 5.56% |
| 2013 Q1 | 1.09 Billion USD | -7.31% |
| 2013 Q2 | 1.11 Billion USD | 2.2% |
| 2013 Q3 | 1.1 Billion USD | -0.99% |
| 2013 Q4 | 1.25 Billion USD | 13.69% |
| 2013 FY | 4.56 Billion USD | 5.19% |
| 2012 Q4 | 1.17 Billion USD | 15.41% |
| 2012 Q3 | 1.01 Billion USD | -6.86% |
| 2012 FY | 4.33 Billion USD | 2.43% |
| 2012 Q2 | 1.09 Billion USD | 4.49% |
| 2012 Q1 | 1.04 Billion USD | -7.1% |
| 2011 FY | 4.23 Billion USD | 18.17% |
| 2011 Q1 | 983 Million USD | 0.0% |
| 2011 Q2 | 1.07 Billion USD | 9.26% |
| 2011 Q3 | 1.04 Billion USD | -2.33% |
| 2011 Q4 | 1.12 Billion USD | 7.44% |
| 2010 FY | 3.58 Billion USD | 29.78% |
| 2009 FY | 2.76 Billion USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | -10836.6% |
| Dynavax Technologies Corporation | 232.28 Million USD | -3578.256% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -1306.371% |
| Perrigo Company plc | 4.65 Billion USD | -83.521% |
| Illumina, Inc. | 4.5 Billion USD | -89.698% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 80.064% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -718487.048% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 94.214% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 42.979% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -6625.229% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 34.864% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 2.95 Billion USD | -188.999% |
| Biogen Inc. | 9.83 Billion USD | 13.132% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -4748.155% |
| Evolus, Inc. | 202.08 Million USD | -4127.924% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -40647.806% |
| bluebird bio, Inc. | 29.49 Million USD | -28865.658% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -7244.371% |
| FibroGen, Inc. | 147.75 Million USD | -5682.663% |
| Agilent Technologies, Inc. | 6.83 Billion USD | -25.04% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 128561.885% |
| Geron Corporation | 237 Thousand USD | -3604963.291% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | -367.321% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -2039.445% |
| Myriad Genetics, Inc. | 678.4 Million USD | -1159.434% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -23453.411% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -244014.286% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | -125.536% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | -253.171% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 13.428% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -984.75% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -99561.729% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 90.12 Million USD | -9380.482% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -3057.428% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -27241.675% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | -587.184% |
| OPKO Health, Inc. | 863.49 Million USD | -889.467% |
| Exelixis, Inc. | 1.83 Billion USD | -366.832% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | -352.758% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -1671.236% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | -53829.18% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 249.38 Million USD | -3326.097% |
| Insmed Incorporated | 305.2 Million USD | -2699.402% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -930.325% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -31753.26% |
| TG Therapeutics, Inc. | 233.66 Million USD | -3556.564% |
| Incyte Corporation | 3.69 Billion USD | -131.191% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -714.257% |